Synthes announces continued strong growth - third quarter 2005 sales results
Solothurn/Switzerland, October 13, 2005Synthes 2005 consolidated sales for the third quarter of $514.3 million and nine-months year to date of $1,540.8 million represent an increase of 13.8% and 17.6%, respectively, over the prior year (13.4% and 16.1%, respectively, in local currency).
Pro forma for the acquisition of Mathys’ Osteosynthesis business as though the acquisition had occurred on January 1, 2004, consolidated sales represent an increase over the prior year of 14.4% for the third quarter and 16.1% for the nine-months year to date (13.9% and 14.6%, respectively, in local currency).
Key Figures (unaudited)
|
 |
Continued growth in all segments and regions driven by expanded sales force and increased training activities
The Trauma and CMF divisions growth in the third quarter / nine-month year to date 2005 continued to outpace the market. Additionally, the introduction of the Trochanteric Fixation Nail (TFN) product line, Expert Intramedullary Nail product line family (the Expert Tibia Nail in particular) and the successful introduction of the Locking Compression Plate (LCP) product line, thus far, are the primary drivers of the continuing growth in the Trauma division. The Spine division showed continued growth over the prior year primarily due to increased sales in the Anterior Thoracolumbar, Deformity and Biologics segments.
Synthes: A leading medical device company
Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.
For further information please contact
Peter Fehlmann, Investor Relations, Synthes, Inc.
Phone: +41 32 720 48 10 , Fax: +41 32 720 48 11
e-mail: ir.info@synthes.com